BioCentury
ARTICLE | Clinical News

Symbicort regulatory update

January 27, 2017 4:34 AM UTC

AstraZeneca said FDA granted 6 months of pediatric exclusivity to Symbicort budesonide/formoterol. The product is approved to treat asthma in patients ages ≥12 and as maintenance treatment of chronic ...